Day 2

PURE: Cardiovascular disease contrast between developed and undeveloped countries.

80% of the global burden of cardiovascular disease is located in countries with low or middle incomes....

SAVOR-TIMI 53: Saxagliptin showed no cardiovascular benefit

The cardiovascular safety and efficacy of some hypoglycemic including saxagliptin (Onglyza), an inhibitor of dipeptidyl peptidase 4...

ASSURE: Inducing Apo A-1 agent failed to reduce atherosclerotic plaque

Induction apoA-1  synthesis is a new therapeutic approach for the functional HDL particles generation. The RVX-208 induces...

COMPARE: Losartan shows promising results in patients with Marfan syndrome

Patients with Marfan syndrome (connective tissue disorder) are more susceptible to aortic dilation and consequently dissection and...

EXAMINE: The alogliptin is safe for treating type 2 diabetes in patients with a recent history of acute coronary syndrome.

Type 2 diabetes is associated both microvascular and macrovascular disease. Adequate glycemic control can reduce the risk...